XOMA (Nasdaq: XOMA) 37.8% LOWER; offers 052 Phase 2b top line results: glucose control not demonstrated, sees positive anti-inflammatory effect. The trial did not reach its primary endpoint.

Jabil Circuit Inc. (NYSE: JBL) 9.6% HIGHER; reported Q2 EPS of $0.54, $0.03 better than the analyst estimate of $0.51. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.91 billion. Sees Q311 EPS of $0.55 - $0.59, versus the consensus of $0.54. Also sees Q311 revenue of $4.1 - $4.2 billion, versus the consensus of $4.04 billion.

Cintas Corporation (NASDAQ: CTAS) 5.5% HIGHER; reported Q3